Pfizer halted development of its experimental daily weight-loss pill, danuglipron, following a patient's potential liver injury in a trial. The patient's liver enzymes recovered, but the incident, coupled with previous setbacks, led Pfizer to discontinue the drug. While disappointed, Pfizer remains committed to its other weight-loss drug development programs, aiming for a share of the burgeoning GLP-1 market, estimated to reach over $150 billion by the early 2030s. This setback follows the discontinuation of a twice-daily version and another obesity pill last year. Despite this, Pfizer highlighted positive findings from recent studies on danuglipron and emphasized its ongoing commitment to obesity treatment.

Prepared by Olivia Bennett and reviewed by editorial team.